Several companies have reported advancements in cancer diagnostics and treatments. Saga Diagnostics achieved Medicare coverage for its Pathlight molecular residual disease test for breast cancer recurrence monitoring, demonstrating high sensitivity across subtypes. MD Anderson partnered with Toppan Holdings to develop and clinically validate organoid assays for personalized cancer therapy screening. Illumina enhanced its TruSight Oncology assay, adding biomarker detection and reduced sample input for tumor profiling. These developments enhance precision oncology capabilities and support more targeted patient care.